|
Method for reducing lethal action of bacterial lipopolysaccharide in vitro Lipopolysaccharide solution is once exposed to electromagnetic waves at frequency 1 GHz, power density 0.0001 mWt/cm2 for 10 minutes. |
|
Laser coagulation of arteriovenous angiodysplasia is preceded by the intraoperative Doppler measurement of a blood velocity and an arteriovenous shunt diameter. A sphygmomanometer cuff is applied on the shin. A shunt region is located by means of a linear ultrasonic sensor. That is followed by the ultrasound-aided puncture of the arteriovenous shunt. A laser light guide of a diode laser is inserted through a catheter; the cuff pressure is injected until the blood circulation is completely stagnated in the subfacial portion of the arteriovenous shunt. The tissues surrounding the shunt are infiltrated by means of an anaesthetic solution until blood circulation is completely stagnated in the epifascial portion that is followed by laser coagulation. If the shunt diameter is 5 mm or more, the patient is exposed to a laser power of 15 W, and if the diameter is less than 5 mm, a laser power is specified to be 12 W. |
|
|
Method of treating radicular cysts Carious cavity is prepared. Then it is treated instrumentally and antiseptically. A hole of an apical canal of a causative tooth is expanded. Methylene blue is introduced into the cyst through a root canal at a depth of 7-10 min. The cyst envelope is exposed to a laser light generated by a diode laser through the root canal for 30-60 s by means of a needle light guide. The exposure is continued from the vestibular or oral surface for 60.0-120.0 s by means of a plate light guide of intensity 0.5-1 W, wave length 625-630 nm in a pulse mode. Before the root canals of the causative tooth is hermetically sealed, Collap-An gel with metrogil 1.0-1.5 ml is introduced into the cyst. |
|
|
Method of treating corneal keratoconus Method involves corneal impregnation with 0.1% riboflavin and ultraviolet exposure at a wave length of 365-375 nm for 30 min. Before impregnation, the cornea is coated with 40% glucose kept on the corneal surface for 9-11 min; residual glucose is removed, and the glucose-treated corneal surface is coated with 0.1% riboflavin for 30 min. |
|
|
Invention refers to medicine, namely to dentistry, and can be used for treating oral pathologies caused by microorganisms. That can be ensured by applying an oral care composition on a mouth area, which is suspicious for the presence of microorganisms. The above composition contains a photosensitising colouring agent. The colouring agent is specified in a group consisting of riboflavin, red allure, flowing green and lissamine green. Thereafter, this area is exposed to a light at wave length absorbed by the photosensitising colouring agent. The emitted light has the following characteristics: wave length from 400 to 780 nm, dose from 15 to 45 J/cm2, power density from 175 to 250 mW/cm2. The exposure is performed for the period of time from 2 to 15 min. |
|
|
Method of making targets with same radioactivity (versions) Present invention relates to a method of making targets with the same radioactivity. The disclosed method according to an embodiment of the invention includes mounting targets (600) on a holder comprising multiple substrates (102) with openings (202) having an array of cells. The distribution of targets on the cells is carried out based on a known flux value in a reactor core for facilitating corresponding irradiation of targets with the flux depending on arrangement thereof in said array of cells. The holder can be placed within the reactor core to enable irradiation of the targets. |
|
Device for coherent radiation of human body with therapeutic effect Invention refers to medical equipment. A device for coherent radiation of a human body with the therapeutic effect aims at stimulating the favourable therapeutic effect of the electromagnetic, optic and acoustic radiation on the human body by the same device. The emitters are used simultaneously in certain coordinated electric and geometric configurations for producing high therapeutic results. The electronic control of voltage, frequency, modulation and spatial geometry of the emitters provides coordinating the modes of radiation having the favourable effect on the human cellular tissue. In the preferential version, the device is held in a hand with the use of a set of specific nozzle tips for external and internal use in various parts of the human body. |
|
Invention refers to medicine, namely to pulmonology, and can be used for the correction of secondary mucociliary insufficiency (MCI) of the lower airway (LA) in the patients with bronchopulmonary diseases. A projection of bronchi and lungs in sub-clavian region, interscapular space and axillar region from both sides is exposed to a pulsed low-intensity infrared laser light at wave length of 0.89 mcm. A degree of mucociliary insufficiency is pre-determined. The exposure is characterised by an average-power emission of 3.75 mW at pulse repetition frequency 500 Hz. Degree 1 secondary mucociliary insufficiency of the lower airway requires 7 or 8 6-minute sessions. Degree 2 implies 7.5-minute sessions in number of 9 or 10. If observing degree 3, 11 or 12 daily sessions last for 9 minutes every day. |
|
Invention refers to medicine, namely to pulmonology, and can be used for the correction of secondary mucociliary insufficiency (MCI) of the upper airway (UA) in the patients with bronchopulmonary diseases. Mucous membranes of the nasal cavity from both sides are exposed to a low level red light laser therapy at wave length of 0.633 mcm in a continuous mode. That are preceded by diagnosing and determining degrees of the SMCI. Degree 1 secondary mucociliary insufficiency of the upper airway requires the laser light exposure at total power density (PD) 1.5 J/cm2 by 5 or 6 1-minute sessions. Degree 2 implies 1.5-minute sessions in number of 7 or 8 at total PD 2.25 J/cm2. If observing degree 3, 9 or 10 daily sessions last for 2 minutes every day at total PD 3.0 J/cm2. |
|
Matrix laser emitter for physiotherapeutic apparatus Invention can be used in laser therapy for treating persistent and septic wounds, fractures, arthropathies, as well as in cosmetology. A presented matrix laser emitter comprises laser diodes arranged as two lines in the same cavity, a static power supply unit adjusting voltage amplitude, and a controller specifying three pulse repetition frequencies, with a base frequency of 10000 Hz and an additive modulation frequency of 1000 Hz and 1333 Hz. |
|
Method of treating locally advanced oropharyngeal cancer Treating locally advanced oropharyngeal cancer is ensured by a radiation therapy in the mode of dynamic dose fractionation. The radiation therapy is started by supplying a fraction dose of 2.4 Gy. After 2 days of treatment gap, the patient is exposed to total fractions at a fraction dose of 3.6Gy for three days. Each session is precede by placing high-structure hydrogel matrix of sodium alginate under a patient's tongue with metronidazole 150mg and bilberry 20-35mg pre-introduced into the matrix, for 4-5 hours twice every 1-2 hours. The two following sessions of the exposure at a fraction dose of 2.4 Gy are preceded by placing the matrix once under the tongue for 4-5 hours. After 2 days of treatment gap, the following 5 sessions of the radiation therapy are performed at a fraction dose of 2.4 Gy to a cumulative dose of 30Gy. Colegel-DNA-Ch high-structure disk is preliminary placed under the tongue for 4-5 hours. |
|
|
Method for photodynamic therapy of oncological diseases Invention refers to medicine and can be used to select individual radiation-measuring parameters of a laser therapy of an individual's tissues. The tissue is exposed to a broad-band visible and near-IR radiation. The tissue diffuse reflection spectrum is measured. The tissue diffuse reflection spectrum shows its structural-morphological parameters, including the tissue concentration of blood vessels fbl and photosensitiser Cps, as well as the relative blood contents of oxyhaemoglobin S and methaemoglobin CMetHb. The tissue spatial brightness spectrum F(z, λ) is stated with using a tissue optical radiation transfer model and the derived values of its structural-morphological parameters. Wave lengths and laser light powers, as well as the tissue exposure time providing the greatest light absorption by the photosensitiser and the best oxygen generation at a depth of a pathological segment of the tissue or throughout with the minimal exposure of the laser light on the healthy tissue are derived from distributed light absorption efficiency by the photosensitiser Kps(z, λ) and photochemical dissociation efficiency of oxyhaemoglobin n(z, λ) by the light wave length λ and the tissue depth z calculated by expressions: Kps(z, λ)=Cpsεps(λ)F(z, λ), n ( z , λ ) = f b l S ( C t H b / μ t H b ) ε H b O 2 ( λ ) Ф ( z , λ ) ( q λ / h c ) , wherein εps and ε H b O 2 are molar absorption coefficients by the photosensitiser and oxyhaemoglobin, CtHb=150 g/l is the average blood haemoglobin concentration, µtHb=64500 g/mole is the molar weight of haemoglobin, h is the Plank's constant; c is a light velocity in the medium; q is a quantum yield of photochemical dissociation of oxyhaemoglobin. |
|
Candida yeast-like fungi are measured. Lamypharen biogel is used to cover approximate dental surfaces along the quadrants (1.2) and (3.4) or (1.5-1.8, 1.4-2.4, 2.5-2.8), (3.5-3.8, 3.4-4.4, 4.5-4.8), into a gingival surface, inflamed surfaces of a gingival crest or into a gingival pockets. The exposure makes 20 to 30 minutes. After the gel is removed by means of Alod - 01-GRANAT diode laser, the gingival papillas or gingival pockets are treated. If the measured Candida yeast-like fungus content is 105-107 CFU/tampon or CFU/ml, the exposure length makes 2 minutes. If the measured value is 103-104 CFU/tampon or CFU/ml, the exposure length is 1 minute. What is used is a laser light at wave length 662nm with a radiation power of 0.4Wt, a power density of 14-18 J/cm2 in a continuous mode. That is followed by Lamypharen biogel applications on the gingival mucosa, into the gingival pockets covered with a protective dressing for 1-2 hours. The therapeutic course makes 3 procedures. Besides, Lamypharen biogel is administered orally once a day 30 minutes before a meal in an amount of 20 g for 14-30 days depending on a severity of the disease. |
|
|
Method for conservative treatment of external colonic fistulas Patients keep a diet with reducing an amount of liquid taken up to 1.5l a day that is compensated by the intravenous administration of solutions an amount and composition of which depends on a degree of water-electrolyte disturbances. Additionally, after bandage removal, the wound and edges of the fistulous passage is 5% potassium permanganate, which is then washed with 3% hydrogen peroxide. A mouth of the fistula and the wound edges are dried. That is followed by an aeration of the mouth of the fistula with a cooled plasma flow of nitrogen monoxide at a depth of 0.5cm in the therapeutic mode of 2000 mg/m3 and exposition of 1.5min. The mouth of the fistula and the wound edges are treated with a plasma flow of nitrogen monoxide in the concentration within the contact area with the wound surface of 1500 mg/m3 and time of exposure of 20 seconds per each 1 cm2 of the surface. The mouth of the fistula and the wound edges are dried. The mouth is packed with the gauze swab. The fistulous wound is exposed to EHF waves with the pure noise spectrum and the provided integral power on the wound surface of 1.5 mcWt along the perimeter of the mouth at 15mm from the fistulous passage for 30 minutes. The swab is removed. The mouth and the surrounding skin is treated with zinc paste and covered with gauze swabs. The further bandages are performed in the similar way as the bandage wets with the intestinal contents, but no more than 2 times a day and at least once every 3 days. |
|
|
Method of treating patients with rheumatoid arthritis Composite application of therapeutic preparations is combined with a laser therapy. A basic anti-inflammatory preparation is presented by methotrexate administered subcutaneously in a dose of 15mg once a week, and folic acid administered orally in a dose of 5mg a week. Movalis is additionally prescribed in the form of intramuscular injections in a dose of 15mg once a day. The laser therapy is differentiated depending on a degree of the disease, a degree of endothelial dysfunction manifestation, namely a von Willebrand factor (vWF), haemostasis system activity indices, namely activated partial thromboplastin time (APTT), prothrombin time (PTT), thrombin clotting time (TCT), antithrombin III (AT III), protein C. If observing the degree I of the disease, APTT 30.6±1.5 sec or more, PTT 19.2±0.9 sec or more, TCT 15.1±0.7 sec or more, AT III 92.8±7.6% or more, protein C 0.92±0.02 or more, vWF 108.9±9.6% or less, 6-8 daily procedures of the intravenous laser blood irradiation, on the first day for 15 minutes at wavelength 0.365mcm, on the following day for 5 minutes at wavelength 0.405mcm, radiant power at a light guide end 1.5-2.0mV in a continuous mode; the procedures are alternated every second day. The degrees II and III of the disease, APTT 22.2±5.5 sec or less, PTT 12.8±1.7 sec or less, TCT 11.2±0.9 sec or less, AT III 85.4±1.1% or less, protein C 0.84±0.02 and less, vWF 133.5±2.2% or more, require performing 10 daily procedures of the intravenous laser blood irradiation, on the first day for 15 minutes at wavelength 0.365mcm, on the following day for 5 minutes at wavelength 0.405mcm, radiant power at the light guide end 1.5-2.0mV in a continuous mode; the procedures are alternated every second day. |
|
Method for photodynamic therapy of oncological diseases Composition of 5,10,15,20-tetrakis(N-methyl-3'-pyridyl)chlorine and 5,10,15,20-tetrakis(N-methyl-3'-pyridyl)bacteriochlorine is administered into a tumour tissue as a photosensitiser in an amount of 0.5-10mg per 1g of tumour tissue depending on a degree of tumour differentiation. The laser exposure starts 20-40 minutes later at wave length 760-762 nm. The cytological examination follows 6-7 days later, and if observing signs of persistent tumour growth, the presented therapeutic session is repeated. |
|
Photosensitisers for photodynamic therapy Invention refers to medicine, namely to a photosensitiser for photodynamic therapy. What is declared is methyl ester 13,17-bis(N-methyl-N,N-diethylammonioethylamide) chlorine e6 ditosylate as a photosensitiser having formula: . |
|
Method of treating bronchoesophageal fistulas Method involves the endoscopically controlled introduction of Coletex-D gel into a fistulous passage from the oesophagus until filled completely. The following exposure to a laser light at wavelength 0.66 mcm, output power 15-45 mWt/cm2 covers a fistulous passage mouth for 5-7 minutes to be repeated in the same mode every second day. The course of the laser light exposure makes 8-10 procedures. |
|
|
Method of recovering binocular vision in case of concomitant strabismus Invention relates to medicine, ophthalmology and is intended for recovery of binocular vision in case of concomitant strabismus. Stimulation of retina is performed by observation by patient of four-point laser speckle with Polaroid separation of vision fields on diploptic apparatus, with relaxation and loading with respectively positive and then negative spherical lenses with 0.5 diopter step until binocular fusion takes place. Stimulation is carried out by laser speckles in pulse mode, with application successively of first green speckles for 2 minutes to stimulate parafoveal and macular zones of retina, and then red ones for 2 minutes to stimulate foveal zone of retina with5-minute interval between them, with pulse frequency 5 units lower than critical frequency of flicker fusion. Course of treatment constitutes 10 sessions. |
|
|
Invention refers to medicine, namely to ophthalmology and ophthalmic oncology, and can be used for the prevention of the haemorrhagic complications accompanying an endoresection of intraocular new growths. That is ensured by a post-vitrectomy barrier circular continuous laser coagulation of the retina and choroid in the PFOS environment until a whitish coagulation trace is visualised on the retina. A tumour border is spaced at 2.0 mm. The laser coagulation trace is followed by perform a circular continuous retinochorioectomy. An electrolysis session of the intraocular new growth is performed in the air environment at current intensity 20 mA with using extrascleral and intraocular electrodes. |
|
|
Method for photodynamic processing of scleral bed following endoresection of intraocular new growth Endoresection of an intraocular new growth is followed by covering the scleral bed surface with a photosensitising gel (PS gel) containing 0.1% monoethylene diamine monoamide chlorine adipate e6. The PS gel exposure makes 3 minutes. Thereafter, the scleral bed is exposed to laser light at a wave length of 662 nm, light dense of 60 J/cm2, with the fields of 4 mm in diameter in an air medium with the exposure covering the 1.5 mm surrounding tissues. The exposure is circle-wise from the periphery to the centre and covers the adjoining fields by 5% of the area. |
|
|
Invention refers to medicine, namely to ophthalmology and ophthalmic oncology, and can be used for the scleral bed treatment following an endoresection of an intraocular new growth. To this effect, the endoresection of the intraocular new growth is followed by applying an active point of one needle electrode on the surface of a scleral bed in parallel to a retinotomy border at 0.5-0.7 mm therefrom. A second electrode is applied in parallel to the first one at 3-4 mm towards the centre of the scleral bed. An electrolysis is performed at current intensity 5 mA for 10 seconds. That is followed by moving the electrodes gradually along the surface of the scleral bed, first circularly in parallel to the retinotomy border, and then from the periphery to the centre. The electrolysis covers the entire area of the scleral bed at current intensity 5 mA for 10 seconds in each electrode position. |
|
|
Method of treating cardiovascular diseases With the underlying conventional drug therapy, the patient is exposed to millimetre-wave electromagnetic emission at the molecular spectrum frequencies of oxygen emission and absorption spectra with the exposure localised within the xiphoid appendix. The exposure time is 3 minutes continuously within one session. The output emissive power is 500 mcW at the power density on the skin surface of 17.4 mcW/cm2. A distance of the exposure point and an object is specified to be equal to 4 cm. The therapeutic course makes 7-10 sessions, one session a day. |
|
Method of treating lumbar radicular pain syndrome Method involves a temporary catheterisation of an epidural space. An X-ray controlled light guide of a low-intensity laser light apparatus is inserted into the epidural space directly about the injured spinal nerve root. A laser light therapy of the directly injured spinal nerve root through the light guide inserted in such a manner. At least 10 20-25-minutes daily procedures of the low-intensity laser light emission are performed. |
|
Method of radiotherapy of prostate gland cancer recurrences after radical prostatectomy Invention relates to medicine, radiotherapy and deals with treatment of prostate gland (PG) cancer recurrences after radical prostatectomy. Method includes irradiation of zones of regional metastasis, bed of ablated PG and zone of recurrence. Irradiation is performed in mode of hypofractionation with application of radiotherapy with modulation of intensity by dynamic arches according to the principle of "simultaneous integrated boost" simultaneously on zones of regional metastasis SFD 1.8 Gy, bed of ablated prostate gland SFD 2.35 Gy and recurrence zone SFD 2.5 Gy. Irradiation in quantity of 26 fractions is carried out 5 times per week. |
|
|
On the third postoperative day, coagulogram values are determined: r is a value reflecting the pro-thrombin blood activity and the time of the clotting reaction initiation; a fibrin-thrombocyte constant AM and the total fibrinolytic activity F. What is involved is an intravenous laser blood exposure at a wave length of 0.63 mcm, light guide end power of 1.5-2 mW with underlying conventional drug therapy. If r=3.9±0.17 min, AM=737.43±4.35 relative units, F=21.46±0.48%, the procedure length makes 20 minutes; the sessions are performed three times every second day. In the patients with blood coagulogram values r=2.9±0.17 min, AM=837.85±3.75 relative units, F=26.43±0.78%, the procedure length is 30 minutes; the therapy is performed for 5 days after the operation daily. |
|
|
Method of treating cerebral arteriovenous malformation Brain angiography is performed to find an intraglomerular region of the most significant afferent vessel of the arteriovenous malformation (AVM). That is followed by the stereotactic single exposure to a through proton beam of a power of 1000 MeV with delivering a dos field of 40-60 Gy to an isocentre. |
|
Method of treating cerebral arteriovenous malformation Brain angiography is performed to find an intraglomerular region of the most significant afferent vessel of the arteriovenous malformation. That is followed by photon stereotactic therapy by the exposure of this region during the sessions 3 times a week in a dose of 6-7 Gy to a total basic dose of 36-42 Gy. |
|
Method of treating central obstructing tracheal and bronchial tumours Invention refers to medicine, namely to oncology and can be used in treating central obstructing tracheal and bronchial tumours. A bare metal-frame endoprosthesis is implanted into the place of the obstructing tracheal and bronchial tumour to recanalise a tracheal or bronchial lumen. Observing a tumour tissue prolapse through an endoprosthesis wall requires performing an argon plasma coagulation procedure at power 35-45 Wt. |
|
|
Method for normalising individual's diurnal rhythm Combined therapeutic exposure aiming at increasing an individual's blood melatonin circulation is performed. At 6 p.m., 15-minute Power Plate training is performed. The training follows the regimen: vibrating plate vibration frequency is 30 Hz, one exercise length is 30 sec, the plate shift amplitude is 2 mm, gravity is 1.83 G, pulsed acceleration is 18.00 m/s2. At 6.30 p.m. the patient takes the food stuff 'Samarskiy Zdorovyak' 60g/day to 90g/day, which is prescribed according to the composition depending on the individual's disease. From 7 p.m. to 8 p.m. the patient wears glasses having the function of light radiation within the lenses at a wave length of 480±5 nm to 490±10 nm. The therapeutic sessions are performed once a day from 6.00 p.m. to 8.00 p.m. The length of the course is 1 month three times a year in autumn, winter and spring. |
|
Invention refers to medicine, namely to urology and balneotherapy, and can be used for treating patients with benign prostatic hyperplasia complicated by chronic prostatitis with a dominant symptom of nocturia. That is ensured by performing EHF therapy. The above is combined with an integrated resort treatment: oral administration of carbonate-hydrocarbonate-sulphate sodium-calcium low-mineralised (3.6-3.7 g/l) water in an amount of 280-300 ml three times a day 40-45 minutes before meals. The balneological treatment is prescribed: taking baths with similar mineral water at a temperature of 36-37°C with the exposure of each procedure 15 minutes in the number of 8 procedures every second day. Phytomicroenemas are prescribed in the number of 8 procedures every second day. That is combined with drug therapy with artesine 2 mg/day for 10 days. |
|
Apparatus comprises a visible light emitter and a control system. A light emitter comprises a continuous light source and an intermittent light source configured to overlay the light on the continuous light generated by the continuous light source. The control system comprises a frequency control unit configured to increase a frequency of the intermittent light source over one cycle of frequency variations from an initial frequency that is below an optical boundary of merging to a target frequency that is above the optical boundary of merging, as well as increase the frequency within the range of 45 Hz for at least 5 minutes over one cycle of the frequency variations. |
|
Cosmetic product for microelement photophoresis Main active factor of a photophoresis apparatus is an effect of a linear spectrum of a number of chemical elements emitted by a cathode so that gross power makes approximately 1 mW. The apparatus comprises an anode and a hollow cathode enclosed in a hermetic cylinder filled with inert gas and provided with a glass output window; the cathode comprises chemical powders aggregating a multiple-element linear emission spectrum of the cathode with evident spectral lines characteristic for the chemicals placed on the cathode: calcium, magnesium, potassium, sodium, manganese, copper, zinc, iron, selenium, silicon, platinum. |
|
Method of treating herpetic keratitis Solution containing, wt % riboflavin mononucleotide 0.09-0.11, chitosan succinate 9.5-10.5, sodium chloride 0.8-0.9, tris-(hydroxymethyl)-methylamine 0.08-0.12, Nipagin 0.0075-0.0125, Trilon B 0.005-0.01 and purified distilled water is instilled for 15 minutes. That is followed by 6 cycles of the 5-minute ultraviolet light exposure of the cornea of 30 minutes in total at a wavelength of 370 nm and power 3 mW/cm. That is combined with instilling the same solution for three cycles. |
|
|
Method for experimental assessment of millimetre-range electromagnetic waves (ehf) effect Invention refers to experimental medicine and immunology, and can be used for the assessment of the millimetre-range electromagnetic wave (EHF) effect within a three-component model of cytostatic exposure. That is ensured by a thymus exposure in the group of animals to the millimetre-range electromagnetic wave (EHF) effect at wavelength 5.6 mm for 2 weeks every 1-2 days. A single exposure of the physical factor makes 1-2 minutes for 2 weeks every 1-2 days. That is followed by simulating a surgical intervention by opening and closing a peritoneum. On the seventh postoperative day, the animals are exposed to three-fold fractionated external gamma exposure in a single dose of 2.5 Sv every single day. Thereafter, cyclophosphan is administered intraperitoneally in a dose of 4 mg/100 g of animal's body weight. On the 14th day after the cytostatic is administered, the animals are killed to examine their blood and immune competent organs. That is combined with determining a thymus cellularity (TC) in 106cell./100 mg of its weight, a functional lymphocyte activity in a nitroblue tetrazolium test (NTT) in units, a spleen antibody-forming cell (AFC) count according to N.K.Erne in cells/"чП", apoptosis in an annexin test (AT), %, blood serum circulating immune complex (CIC) in units. That is followed by calculating a physical factor effect index (FI) by formula: F I = A T × N T T × T C × 100 C I C × A F C . If the FI is less than 48, the presence of the immunomodulatory effect of the EHF-exposure is stated. |
|
Method and device to monitor process of injury treatment Invention relates to facilities for monitoring of injury treatment process. A monitoring device comprises a unit of injury nitrogen oxide level monitoring, a unit of controlling signal generation by means of comparison of a nitrogen oxide level with preset threshold and unit of correction of light dosing for injury treatment, at the same time the monitoring unit is designed to detect magnetic field produced as a result of transition from Fe2+ into Fe3+, production of Fe3+ level in accordance with magnetic field, calculation of met Hb level in accordance with the level of Fe3+ and calculation of nitrogen oxide level in accordance with proportionate ratio between the level of met Hb and level of nitrogen oxide. The injury treatment device comprises several sources of light and a monitoring device. |
|
Method of treating locally advanced unresectable pancreatic cancer Treating locally advanced unresectable pancreatic cancer is ensured by arterial chemoinfusion with the use of the preparations Gemzar 1,000 mg/m2/30 min and Eloxatin 50 mg/m2/120. The infusion is cyclic at least 2 months apart. The 1st to 4th arterial chemoinfusion cycles precede a radiation therapy, and no later than within 3 months in the same regimens - after the radiation therapy to disease progression. The radiation therapy is conformal and performed not earlier than 1 month after the first 1st-4th arterial chemoinfusion cycles at a single radiation dose of 3 Gy 5 times a week to a total radiation dose of 51 Gy. |
|
|
Laser therapeutic device comprises a laser light source with at least one laser, a laser waveguide connected to the laser light source, and an optical system for beam formation having a rotating component. Between the laser light source and an output end face of the waveguide, there are optically connected series first objective a distance from which to an input end face of the waveguide is less than its focal distance, waveguide and second objective behind the output end face of the waveguide with its aperture fitted an aperture of an incident ray bundle, collimator comprising a negative lens and an objective a collimated bundle of which comprises a diffraction element, e.g. diffraction grating. |
|
Fibre-optic tool with curved distal working part Distal portion of an optical fibre is placed in a ferrule with spacing on the entire length and the end of the optical fibre is welded onto the inner surface of the welded portion of the ferrule. The required radiation distribution at the output of the tool can be obtained by varying the thickness of the welded portion of the ferrule and the shape of the external optically refracting surface. |
|
Apparatus for extracorporeal blood and red cell processing Invention refers to apparatuses for intraoperative extracorporeal blood processing. The apparatus comprises ultraviolet sources, a transparent plastic tray exposed to an excessive pressure of not less than 150 mmAq from the inside and provided with nozzles connected to a blood and packed red cell return system. The apparatus accommodates a pressure sensor and a control unit. The tray represents a flat elastic bag surfaces of which are welded to form a serpentine passage. The blood and packed red cell return system is provided with a soft container and a clamp at the top. The bottom of the blood return system comprises a loop with an injection needle attached at the end. The pressure sensor is arranged on the surface of the soft container and coupled with the control unit connected to the ultraviolet source with a variable intensity. |
|
Method of treating tuberculous spastic microcystis Treating tuberculous spastic microcystis with underlying anti-tuberculosis chemotherapy requires peridural anaesthesia 5-7 days long. That is combined with the exposure to a laser light at a wave length of 632 nm of power 12 mW covering a biologically active point of the urinary bladder on a hand. The 4-minute exposure is daily for 5-7 days. |
|
|
Method of producing ceramic from ytterbium oxide Ceramic is produced from ytterbium oxide by moulding a workpiece from ytterbium oxide powder (Yb2O3), followed by thermal and thermobaric treatment. Thermobaric treatment is carried out in the region of thermodynamic stability of a cubic phase or monoclinic phase of ytterbium oxide in the pressure range of 2.0-8.0 GPa and temperature in the range of 600-1500°C while holding for 5-100 s. When carrying out the pressure method, phase composition can be intentionally changed from pure cubic to pure monoclinic phase with ceramic density of 9.0-10.0 g/cm3. |
|
Device for infrared exposure on collagen layer of human skin with visualising of process Invention refers to medicine and concerns a device for the infrared exposure on the human skin. The device is presented in the form of a magnetic resonance tomographic scanner and comprises a receive/transmit channel, a three-dimensional localisation unit, a microprocessor controller and a display. The device is also provided with a local exposure unit presented in the form of a manipulator with an IR laser, a lens and a marker for laser beam binding to a coordinate system of the analysed area. |
|
Method of treating infected wounds and fistulas in oncological patients Treating a wound surface with dioxidine is followed by an infrared laser light with a permanent magnetic field not earlier than 5 days after the operation. Magnetic induction intensity is within the range of 20-50 mT; a laser pulse repetition frequency is within the range of 80 Hz, and a power is 0.25-0.5 W. The whole postoperative area is subject to the daily distant labile exposure to a defocused beam at 0.5 cm for 30-60 seconds. That is followed by applying tissues with hypertonic solution 3 to 5 times a day; the therapeutic course is 10-15 procedures. |
|
|
Method of treating patients with dental pulp and periodontal diseases Endodontic treatment stage involving retrieval and dilation of a root canal is performed. Gluftored liquid is introduced into the root canal of the tooth. A fibre cable is placed above a tooth canal orifice, and the liquid is reflected by means of a laser light for 30-60 seconds. The root canal is dried with a paper point. Pre-shaken Gluftored suspension is introduced into the root canal. The fibre cable is placed above the tooth canal orifice, and the suspension is reflected by means of the laser light for 30-60 seconds. The root canal is dried and filled. |
|
Method of treating local recurrence of pancreatic cancer following radical surgery Chemotherapy is conducted with using the preparations Gemzar 1000 mg/m2/30 min and Eloxatin 50 mg/m2/120 min. The chemopreparations are administered by arterial infusion cycles at least every 2 months. 1 to 4 arterial chemoinfusion cycles precede a radiation therapy, and no later than within 2 months in the same regimens - after the radiation therapy to disease progression. The radiation therapy is performed not earlier than 1 month after the first 1-4 arterial chemoinfusion cycles at a single radiation dose of 3 Gy 5 times a week to a total radiation dose of 51 Gy. |
|
|
Method of physiotherapeutic treatment of patients with diabetic neuropathy of lower extremities Light therapy with red-infrared radiation from the apparatus "Geska-1" is carried out. A wavelength of red radiation is 660-675 nm, and the total density of radiation power is not less than 4 mW/cm2. A wavelength of infrared radiation is 840-950 nm, and the total density of radiation power is not less than 15 mW/cm2. An area of irradiation of an emitter is 4 cm2. An impact is performed on the back and sole areas of feet for 2-4 minutes on each area, on the area of the popliteal fossa for 2-4 minutes on each extremity, on the area of the spine at the level of segments L2-L4 paravertebrally from two sides for 2-4 minutes from each side. An impact on feet is performed daily; an impact on the popliteal fossa area and the area of the spine is alternated every other day. The total time for a procedure constitutes 12-24 minutes, daily, with a course of 10 procedures. |
|
|
Invention refers to medicine, rehabilitation, physiotherapy, namely to - electrical therapy. A body is exposed to an electron flow generated by at least one electrode parameters of which are specified within: current intensity up to 50 mA and current frequency from zero to 1.7×1015 Hz. At least one ground electrode with constant or variable resistance specified within 1×10-2 Ohm to 2×109 Ohm included, and at a frequency from zero to 1.7×1015 Hz is additionally applied on the body. The body can be additionally exposed to electromagnetic waves at a frequency specified from zero to 1.7×1015 Hz. Before the electrodes are applied on the body, an application point of at least one electrode is coated with a drug or a biologically active substance. At least one negative electrode is switched at least once, so the electrode becomes ground, and at least one ground electrode is switched and becomes the negative electrode. |
|
Apparatus for remote neutron therapy Apparatus for remote neutron therapy is intended for treating of radioresistant forms of oncologic diseases. Its construction includes a base, providing ±180° rotation of a balanced console with a neutron head. The neutron head consists of a neutron generator, a radiation protection with an in-build in it neutron channel. In the generator as a source of neutrons a nuclear reaction 3T(d,n)4He is applied. The neutron head is placed on the balanced console with a mechanism of its longitudinal travel. Different sizes of neutron fields on the patient's body are formed by means of wedges. To measure the distance from the source of neutrons to the patient there is a laser or a microwave ruler and a video camera with LEDs for visualising superposition of the marked contour of irradiation on the patient's body with an image of the output opening of the neutron channel. To reduce an impact of directed radioactivity on the attendant personnel the cooled substrate of the target and walls of the neutron channel are made from selected materials, also introduced is a protective box for placement of the neutron head in it by a robotised device during the patient's positioning. |
|
Method of treating destructive forms of chronic apical periodontites Invention relates to medicine, in particular to dentistry, and can be used for treatment of destructive forms of chronic periodontites of single-rooted and multi-rooted teeth. An access to the area of periodontitis is formed. Laser irradiation is carried out by passing the laser lightguide into the periapical space to the area of periodontitis in a pulse-periodic mode. The wavelength is 980 nm, irradiation is carried out for 30-60 s with reciprocating movements of the lightguide and laser radiation power 0.5-0.9 W. After 3-5 days additional irradiation of the periapical space of the periodontitis area by radiation of a low-intensity laser with the wavelength 66 nm, power 200 mW is performed also in a pulse-periodic mode for 2 min. |
Another patent 2541805.